Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/7f/79/63/7f79632d-c741-5657-7b0d-e0f4acf4f28b/mza_1389476964021980757.jpg/600x600bb.jpg

Blood Podcast

American Society of Hematology

353 episodes

1 day ago

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

All content for Blood Podcast is the property of American Society of Hematology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The Blood Podcast summarizes content recently published in Blood, the most cited peer-reviewed publication in the field of hematology.

Science

Health & Fitness,

Medicine

Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

Blood Podcast

9 minutes

2 weeks ago

Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).